By Gary Petersen | Posted - Dec 2nd, 2020

 

 

 

 

ASH 2020: Top 7 Myeloma ASH Abstracts According to Myeloma Specialists

The American Society of Hematology meeting is the largest global meeting where researchers for blood cancers come together to share data from recent studies or discoveries. This year, the meeting planned for San Diego will be held virtually. Researchers submit their summaries (abstracts) and selected research is presented at the meeting in the form of oral presentations, poster presentations or papers. 

So what do Dr. Shaji Kumar of Mayo Clinic, Dr. Parameswaran Hari of the Medical College of Wisconsin, and Dr. Luciano Costa of  UAB O’Neal Comprehensive Cancer Center have in common?  They chose all 7 of the top abstracts reviewed by 15 myeloma specialists. 

Abstract 141 - Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. NDMM KRd+ASCT vs. KRd 12 vs KCd+ASCT

  • Treatment with KRd_ASCT significantly improved PFS compared with both KRd12 and KCd_ASCT. Maintenance with KR also improved PFS vs R.
  • Session: 731. Clinical Autologous Transplantation: Autologous Transplantation: Still the Backbone of Modern Myeloma Therapies
  • Saturday, December 5, 2020: 9:30 AM
  • https://ash.confex.com/ash/2020/webprogram/Paper136907.html

Abstract 143 - Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

  • Long term results of IFM 2009 trial shows similar overall survival after 8 years follow up between early vs delayed transplant in the modern era with VRd therapy. Particularly important info at time of COVID. 
  • Session: 731. Clinical Autologous Transplantation: Autologous Transplantation: Still the Backbone of Modern Myeloma Therapies
  • Saturday, December 5, 2020: 10:00 AM
  • https://ash.confex.com/ash/2020/webprogram/Paper134538.html 

Abstract 177 - CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a BCMA B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

  • Very high response for CAR-T, most appear durable. Very promising.
  • Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma 
  • Saturday, December 5, 2020: 12:00 PM-1:30 PM
  • https://ash.confex.com/ash/2020/webprogram/Paper136307.html 

Abstract 179 - Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

  • MEDDI2228 an anti-BCMA ADC with high rate of response and favorable safety profile, likely better than Belantamab
  • Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma
  • Saturday, December 5, 2020: 12:00 PM-1:30 PM
  • https://ash.confex.com/ash/2020/webprogram/Paper136375.html 

Abstract 180 - Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

  • This is a novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) & CD3 shows activity in relapsed refractory myeloma. High response rates (78%) @ 20-180 mcg/kg dose levels. 
  • Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma 
  • Saturday, December 5, 2020: 12:45 PM
  • https://ash.confex.com/ash/2020/webprogram/Paper138831.html 

Abstract 290 - A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

  • Talquetamab GPRC5D/CD3 TCE. This validates a new target for immunotherapy. Response rate is fantastic and drug can be given subcutaneously.
  • Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents
  • Saturday, December 5, 2020: 2:00 PM
  • https://ash.confex.com/ash/2020/webprogram/Paper133873.html

Abstract 292 - Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

  • BFCR4350 FCRH5/CD3.   Another immunotherapy target validated. Very high response rate for this T cell engager BFCR4350A is a novel bi-specific antibody targeting FcRH5. FcRH5 is universally expressed on plasma cells) and CD3 shows clinical activity in relapsed refractory myeloma. 
  • Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents
  • Saturday, December 5, 2020: 2:30 PM
  • https://ash.confex.com/ash/2020/webprogram/Paper136985.html  

These 7 were most frequently chosen by the group of myeloma specialists, but the group identified a total of 61 abstracts that are important in the myeloma world. We will be covering all things myeloma during the ASH 2020 conference and will share them with you in the coming weeks. Dr. Michael Thompson has put together this consolidated list and we will be posting it on the Myeloma Crowd site as soon as it is finalized.  I just want to thank all those involved who have helped all the #ASH20 participants focus on the most significant abstract affecting the myeloma patient and care team community.  

Related ASH 2020 Articles

 

 
Gary Petersen
About the Author

Gary Petersen - Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS


Thanks to our Myeloma Crowd Community sponsors:

.